Myelosuppression is the dose-limiting side effect for most anti-cancer and many anti-human immunodeficiency virus agents, which can be quantitated with optimized colony-forming assays (granulocyte-macrophage, late erythroid, and megakaryocytic [for murine only] colony-forming units and early erythroid burst-forming units (BFUs)). When applied to new drug development, the assays are used for therapeutic index-based screening (e.g., less myelosuppressive analogues, structure-toxicity studies, new drug leads), interpreting efficacy data from xenotransplant models, and selecting the most accurate animal model for human hematopoietic toxicity. However, other types of assays may be required to identify the mechanism underlying myelosuppression. In clinical trial planning, in vitro colony-forming assays can be used to elucidate schedule dependency of myelotoxicity (which in turn provides clues about mechanism of action), to plan cytokine support, and to estimate dose-escalation effects. The inhibition of colony formation can be measured relative to a compound with known clinical myelotoxicity and schedule dependency to provide some idea of the toxicity expected at particular doses, and the degree of heterogeneity between individuals, during clinical trials. The predictive accuracy of the in vitro data has been proven by validation studies with alkylating agents.
INTRODUCTION
Most anti-cancer and many anti-human immunodeficiency virus (anti-HIV) compounds produce severe myelotoxicity that may be dose-limiting. Thus, it becomes important during the pre-clinical development of such new therapeutics to evaluate their potential toxicity to human hematopoietic tissue. It is also important to determine whether canine or murine marrow more closely models the toxicity of a compound to human hematopoietic progenitors and, therefore, determine which animal model may be most accurate in predicting maximum tolerated doses and the myelotoxicity associated with dose escalation. Confidence in this type of information from animal models could justify more rapid dose escalation and thereby more rapid completion of phase I trials with no compromise in patient safety. Preclinical evaluation of hematopoietic toxicity may also identify the least toxic analogue or, when com-bined with efficacy data, the analogue or compound with greatest therapeutic index in humans.
The Hipple Cancer Research Center developed in vitro technology (7) for quantitatively estimating the toxicity of investigational agents to the progenitors of 4 hematopoietic lineages from murine, canine, and human sources: granulocyte-macrophage (myeloid), late erythroid, and megakaryocytic (for murine only) colony-forming units (CFU-GM, CFU-E, and CFU-Meg, respectively) and early erythroid burst-forming units (BFU-E). To date, only the murine CFU-GM (mCFU-GM) assay has been optimized with recombinant cytokines to produce CVs of < 25%. The development of optimized assays for the remaining murine progenitors, and for human and canine progenitors, is following the mCFU-GM technology.
This technology has predicted correctly that 3'azido-3'-deoxythymidine (AZT) is much more myelotoxic than dideoxyinosine (ddl) on a molar basis (4) . In contrast, some other dideoxynucleosides such as dideoxycytosine (ddC) were shown to be very myelotoxic (4) . This technology has also been used TABLE L-Potential application areas of in vitro myelotoxicity technology pending direct validation in animal models and indirect validation from clinical data. to evaluate the myelotoxicity of drug combinations expected to be used clinically, such as rifabutin plus AZT (12) or L-phenylalanine mustard (L-PAM) plus buthionine sulfoximine (5) as well as anti-cancer agents under development such as fostriecin, hepsulfam, and pyrazine diazohydroxide (6) . In fact, the National Cancer Institute has used such data to plan dose-escalation phase I clinical trials ( 1 ) .
In this article, we discuss the development of optimized mCFU-GM assays and their validation for myelotoxicity testing, some potential applications of this technology in clinical trial planning, and the role of in vitro myelotoxicity testing in new drug identification and development (Table I) . The purpose of this article is to help spawn new uses and a new appreciation of this technology rather than to review comprehensively the field of in vitro hematopoietic toxicology.
METHODS

Materials
All drugs were obtained from the National Cancer Institute drug repository or from the Food & Drug Administration and stored as labeled. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) was obtained from Immunex ; recombinant human interleukin 3 (rhIL-3), recombinant murine GM-CSF (rmGM-CSF), and rmIL-3 from R&D Systems; and Epogen from Amgen. They were prepared as x 100 stock solutions, aliquoted, and stored at -70°C. Cell culture medium was obtained from BioWhittaker; fetal bovine serum (FBS) from ICN (ICN Gold); Trypsin/ethylenediaminetetraacetate (EDTA) solution from GIB-CO ; and dimethylsulfoxide (DMSO), AZT, and gentamicin sulfate from Sigma (cell culture tested). Seaplaque agarose was from FMC Bioproducts and preservative-free heparin from a local pharmacy.
Isolation of Hematopoietic Cells from Human, Canine, and Murine Marrow
Human and canine bone marrow cells were obtained from femoral canal reamings from patients undergoing orthopedic surgery with informed consent under IRB-approved protocols in Dayton, Ohio (7) or from Beagles at Battelle Institute in Columbus, Ohio, using protocols preapproved by the IACUC. The specimens were aspirated by the surgeon and placed in a 50-ml tube containing 20-30 ml of alpha-modified Eagle's medium (a-MEM) with preservative-free heparin at 10 U/ml final concentration. In the laboratory, the marrow cells were isolated by filtration through a sterile nylon mesh (#60) into a sterile centrifuge tube. The sample was centrifuged at 2,000 x g for 10 min, and the supernatant and adipose layers were discarded. Cells were resuspended in a-MEM and layered over 4 ml of Histopaque 1083 in 100-X -17-mm tubes. After 30 min centrifugation at 2,000 X g, the light-density mononuclear cell fraction at the interface was harvested and washed twice in a-MEM. After resuspending in Iscove's modified Dulbecco's medium (IMDM), the nucleated cells were counted in a hemocytometer (cell viability determined to be ~85% by trypan blue dye exclusion). The cell suspension was then adjusted to the desired nucleated cell concentration.
Canine mononuclear cells were cultured for 18 hr in IMDM, 20% FBS, 25 ng/ml rhGM-CSF, and 5 ng/ml rhIL-3 and then harvested with 0.05% trypsin/0.5 mM EDTA after this 18-hr incubation in preparation for clonogenic assays.
Murine marrow cells were obtained from female BDF, mice given water and lab chow ad libitum. The animals were sacrificed according to protocols preapproved by the IACUC at the Hipple Cancer Research Center. The femurs were aseptically removed, the marrow flushed from the femur with IMDM, and the cell suspension triturated to obtain a single cell suspension of desired cell concentration.
Drug Exposure
On the day of each assay, fresh powdered drug was dissolved in a volume of DMSO to result in a x 10,000 stock solution for the highest final concentration. Immediately before using the bone marrow cells, the DMSO drug stock was diluted 1:100 into culture medium and then 1:10 into medium plus 100 ttg/ml gentamicin sulfate. Serial dilutions were made with IMDM containing DMSO and gentamicin sulfate, so that the only changing concentration was that of the drug. For continuous exposures, the resulting x 10 solutions were then added (without filtration) to a final concentration of 10% in a cell suspension, agarose was added, and then The drug solutions were generally not filtered. The negative control was DMSO in medium containing gentamicin sulfate. The positive control was 50 Am AZT (a x 10 stock solution) in an identical concentration of DMSO and gentamicin sulfate as the experimental compounds. This solution also was not filtered. These stock solutions were discarded at the end of the day.
Cell Culture Assays for CFU-GM After thorough mixing, 400 jul of human or canine bone marrow mononuclear cells in IMDM, 20% FBS, 25 ng/ml rhGM-CSF (+ S ng/ml rhIL-3 for canine assays), 10% of a x 10 drug solution or negative control, and 0.3% agarose (Seaplaque, FMC Bioproducts) was pipetted into microwells of a 24well plate containing a 0.4-ml underlayer. The cultures were then allowed to gel at 4°C for 15 min and then incubated at 37°C in a fully humidified atmosphere of 5% C02 in air for 7 days (canine) or 14 days (human). CFU-GM colonies were counted under an inverted microscope as aggregates of 50 gm or greater in diameter. Murine CFU-GM assays s were performed similarly, except that rmGM-CSF was used at 10 ng/ml and the colonies were counted after 7 days.
Cell Culture Assays for CFU-E and BFU-E For murine CFU-E and BFU-E, a 1-ml culture mixture of the following is prepared: 0.3 ml FBS, 0.1 ml of 10% deionized bovine serum albumin (Cohn Fraction V), 0.1 1 ml of I x 10-3 M 2-mercaptoethanol, Epogen (40 U/ml) to 2 U/ml for CFU-E and 4 U/ml for BFU-E, 2.5 x 105 bone marrow cells, 0.1 ml drug solution, 0.1 ml of 5 U/ml thrombin, 0.1 ml of 10 mM CaCl2, and 0.2 ml of 2.5 mg/ml fibrinogen, and IMDM. After thorough mixing, 0.4 ml of the culture mixture is added to a 35-mm Petri dish, allowed to clot, and surrounded with 1 ml IMDM. After 7 days (CFU-E) or 14 days (BFU-E), cultures are stained with benzidine reagents (5) . Aggregates of 8 or more benzidine-pos-itive cells are counted as CFU-E colonies, and BFU-E colonies are defined as aggregates of 60 or more hemoglobin-containing cells.
For hBFU-E, cells are mixed as already described with FBS, drug solution, IMDM, 2 U/ml Epogen, and 0.3% agarose, and, after 14 days, hemoglobinized colonies are counted microscopically.
Cell Culture Assays for CFU-Meg For mCFU-Meg, a 1-ml culture mixture of the following is prepared: 0.2 ml FBS, rmIL-3 (at 10 ng/ml final), 5 x105 bone marrow cells, 0.1 ml drug solution, 0.1 ml of 5 U/ml thrombin, 0.1 ml of 10 mM CaC'2, 0.2 ml of 2.5 mg/ml fibrinogen, and IMDM. After thorough mixing, 0.4 ml of the culture mixture is added to a 35-mm Petri dish, allowed to clot, and surrounded with I ml IMDM. After 6 days, cultures are stained for acetylcholine esterase as described by Du et al (5) .
RESULTS
Optimization and Validation of In Vitro Hematopoietic Assays
Hematopoietic cells from marrow and spleen can be induced to form colonies of each lineage by specifically stimulating them with defined sets of cytokines. Because colony formation requires significant proliferation and differentiation of the hematopoietic cells, the number of colonies that have formed per unit time can be used as an indicator of drug toxicity. Table II lists the performance criteria that are required of these assays to allow quantitative as well as qualitative conclusions about myelotoxicity. These criteria include the stimulation of approximately 100 colonies per assay dish, a CV of <25%, and linearity between colony numbers and progenitor cell numbers plated. Ideally this is accomplished in an assay system where drug and marrow usage are minimized. To date, mCFU-GM assays from both bone marrow and spleen have been optimized in this way. The remaining progenitor assays are currently being standardized using recombinant cytokines but have not yet been optimized.
The optimized mCFU-GM assays have been used to validate the accuracy of the in vitro system. Figure   1 shows the results of an in vitrolin vivo correlation study using a direct alkylating agent (1,3-bis-2chloroethylnitrosourea [BCNU]). In the top panel, the inhibition of mCFU-GM colony formation is graphed as a function of drug exposure or area under the curve (AUC; concentration x time). The inhibition of CFU-GM that resulted from an in vivo exposure to iv injected BCNU was quantitatively predicted by the in vitro assay. Furthermore, the bottom panel shows that the slope of the in vivo exposure-inhibition curve was also quantitatively predicted by the in vitro data. These results validated the accuracy of the in vitro assay, at least for directacting alkylating agents.
Clinical Trial Planning
Normalized Myelotoxicity and Dose-Escalation Effects. The information that can be derived from in vitro hematopoietic toxicity data is best illustrated using two hypothetical drugs (Fig. 2 ). Several conclusions can be drawn from these data. First, although drug 1 is a more potent inhibitor of colony formation than drug 2, it would be expected to be FIG. 2.-An in vitro myelotoxicity analysis of 2 hypothetical drugs. Note that drug 1 would be expected to be less myelotoxic than drug 2 at clinically-targeted plasma concentrations (between Cp~&dquo;aX and Cpmm), even though drug 1 shows more potent toxicity to hematopoietic cells. The 2 drugs exhibit equal slopes in the log-linear ranges of the curves, and so would be predicted to exhibit similar rates of increasing myelotoxicity with increasing dose during phase I trials.
less myelotoxic clinically because the targeted plasma concentrations are in a range that inhibits colony formation by no more than 30%. In contrast, drug 2 would be predicted to be myelotoxic in the clinic even though it is less potent, because the targeted plasma concentrations lie in a concentration range that inhibits colony formation by 5 5-90%. Recalling the validation experiment with BCNU, also note that these two drugs show very similar slopes over the log-linear range of the curves. Thus, they would be expected to exhibit very similar rates of increasing myelotoxicity with increasing dose during dose escalation. By way of example, Table III provides slopes of log-linear ranges of the curves of 6 drugs that have been tested with the in vitro assays. BCNU showed the steepest slope, followed by camptothecins, hepsulfam, fostriecin, and AZT showing intermediate slopes, and finally ddl showing a very shallow slope. Qualitatively, this resembles what has been observed clinically-that alkylating agents provide only a very narrow working range between efficacy and toxicity, whereas ddl seems to be very safe to use in the clinic, at least with regard to the hematopoietic compartment. These data may become useful in planning and justifying more accelerated clinical trials. The in vitro data with human hematopoietic colony-forming cells may provide a more accurate picture of the maximum rate of dose escalation that can be used without compromising patient safety. It may avoid prolonged phase I trials, which result from the inaccuracy of animal models in predicting rates of dose escalation in humans (2) .
Finally, if drug I represents a currently used compound with known clinical myelotoxicity, then the myelotoxicity of the experimental drug, drug 2, can be normalized to drug 1. At the least, this provides a clinical landmark from which to anticipate the myelotoxicity of drug 2 when it enters clinical trials. Figure 3 shows an example of the evaluation of the myelotoxicity of topotecan normalized to the toxicity of 5 4m AZT to hCFU-GM, a concentration of AZT that corresponds to peak plasma concentrations in humans (10) . These data show that at concentrations below 1 nM, topotecan is more toxic than peak plasma levels of AZT. This very low concentration is well below those targeted for clinical trials (> 100 nM) and suggests that prolonged exposure to topotecan, for example, in phase II clinical trials will produce a very severe neutropenia, even at doses much lower than those currently used.
Heterogeneity in Response. Heterogeneity of individuals' responses to a drug's myelotoxicity can also make clinical trials difficulty. Although there are scant data at the present time, the in vitro assays may be able to predict the heterogeneity caused by allelic differences in protein targets within the susceptible cell population in the marrow (one or more CFUs). In particular, the maximum %CV within the log-linear part of the in vitro dose-response curve is expected to provide a quantitative, relative index of heterogeneity. For example, in Fig. 2 , assume drug 1 is a known clinical agent and drug 2 is the investigational agent. By comparing the maximum %CV for drug 2 within the log-linear part of the the AZT control, a concentration well below those targeted for clinical trials. These data predict that topotecan will cause severe myelosuppression. Dotted lines show the mean ± one standard error for 5 Am AZT's inhibition. is 59%. Thus, the heterogeneity of the toxic response of human hematopoietic cells is 3.1 times greater for topotecan than for AZT. It is interesting that the literature reports remarkably &dquo;unpredictable&dquo; myelosuppression over a range of doses of camptothecins (3, 10) . Schedule Dependency. In vitro myelotoxicity assays can also shed considerable light on the scheduled dependency of myelotoxicity. The mCFU-GM assays showed that inhibition of CFU-GM by BCNU, melphalan, and AZT was dependent on both concentration and time of exposure. Figure 4 shows that the inhibition by AZT was purely AUC-dependent, whereas the inhibition of BCNU and melphalan was not. Both of the alkylating agents gave 1-hr exposure curves that diverged away from the continuous exposure curves at concentrations giving high levels of inhibition of colony formation. We next asked whether or not the AUC-dependent toxicity of AZT was characteristic of other deoxypyrimidine drugs. We have reevaluated previously reported data for ddC, 2',3'-didehydro-2',3', dideoxythymidine (D4T), cyclopentenyl cytosine (CPE-C), 5-fluoro-2',3'-ddC (5-F-ddC). For all four of these drugs, inhibition of CFU-GM colony formation was purely dependent on AUC. In contrast, Fig Note that AZT's myelotoxicity is AUC-dependent. BCNU and melphalan, both alkylating agents, exhibit qualitatively similar results, which are different from AZT's. posure to dideoxypurines and to methotrexate. The dideoxypurines showed toxicity dependent only on concentration and independent of time of exposure. Methotrexate showed a fourth pattern of toxicity, in which inhibition of colony formation was more severe following continuous exposure at a given AUC. These data suggest that particular structural classes of compounds will exhibit characteristic schedule dependencies. Pyrimidine analogues exhibit AUC-dependent toxicity, purine analogues exhibit concentration-dependent toxicity, and alkylating agents and antimetabolites exhibit characteristic toxicities that are not dependent on only concentration, exposure time, or AUC. If this conclusion can withstand the test of additional drugs, then it will become possible to deduce the mechanism of action of an investigational agent without any knowledge of its metabolic fate or biochemical site of action. Myelotoxicity assays can be used not only FIG. 5 .-Inhibition of mCFU-GM by ddl, ddA, and methotrexate as a result of 1 hr (solid circles) or continuous exposure time (solid squares). Note that the dideoxynucleosides' myelotoxicity is dependent upon concentration but independent of time of exposure. Methotrexate's profile is distinct from those of the dideoxynucleosides and the drugs shown in Fig. 4 . to determine the optimum scheduling to maximize drug exposure and to minimize myelotoxicity, but also to provide information on mechanism of action and leads for new drug development.
Lineage-Specific Toxicity. In the planning of clinical trials, it would seem important to predict from in vitro data whether or not to expect anemia, neutropenia, or thrombocytopenia, or whether or not the drug will suppress all hematopoietic lineages. This is important in proposing particular cytokines to compensate for the expected myelotoxicity. For example, data in the murine system show that CFU-E is much more sensitive to topotecan toxicity than are CFU-Meg and CFU-GM (Fig. 6 ). It is interesting, in light of these data, that only mild anemia has been described in clinical trials so far in humans (11) . However, it should be noted that these data have been obtained from phase I trials, where drug exposure times have been brief. Because the red blood cell has a very long half life compared to the &dquo;&dquo;&dquo;&dquo;'II vlllijl I B0' 'WI '&dquo;-1&dquo;&dquo;1 ~umF IG. 6.-Inhibition of murine CFU-GM, CFU-E, and CFU-Meg by topotecan. Note that CFU-E is much more sensitive to topotecan toxicity than CFU-GM or -Meg. Topotecan may, therefore, cause anemia, which may not be apparent during phase I trials because of the long halflife of the circulating red blood cell. thrombocyte and the neutrophil, toxicity to the erythropoietic compartment would not be observable until very late into a clinical trial. It is entirely likely that suppression of erythropoiesis by topotecan has been missed in phase I clinical trials but will appear with severity during the phase II studies involving longer drug exposure times.
Animal Modeling of Human Myelotoxicity and Interpretation of Human Tumor Xenograft Models. Recent ability to assay for CFUs from canine, murine, and human marrow makes possible interspecies comparisons of drug-induced toxicity. Currently, there is no rational way to know a priori which animal model will predict human myelotoxicity. Using in vitro assays, however, one can at least determine which species provides hematopoietic cells with susceptibility to drug-induced toxicity equal to that of human hematopoietic progenitors.
For example, we have found that mCFU-GM is much more resistant to topotecan toxicity than are human and canine CFU-GM (Fig. 7) . The Icso for mCFU-GM is about 50-fold higher than that for its human counterpart. These data suggest that the animal modeling of human myelotoxicity will be more accurate in a canine system than in a murine system.
In addition, data such as these provide an interpretation of in vivo data involving human tumor xenografts in nude mice. Data from the literature (8) show that topotecan's ICso for human cancer cell lines is generally 10-20-fold greater in concentration than for hCFU-GM. Murine cancer cell lines are inhibited by similar concentrations, although, as Fig.   FIG. 7. -Inhibition of CFU-GM from murine, canine, and human marrow. Note that murine CFU-GM is much more resistant to toxicity than either canine or human. Thus, canine sytems provide the better model of human myelotoxicity. The resistance of murine hematopoiesis to topotecan toxicity explains why camptothecin analogues are curative in human tumor xenograft models in nude mice. Error bars indicate one standard error. 7 shows, the mCFU-GM is much more resistant to topotecan toxicity. Thus, it is easy to understand why human cancers implanted into nude mice can be cured. At least for topotecan, the nude mouse system is probably giving an artificially high estimate of therapeutic index, which is made possible by the much greater resistance of its marrow to topotecan toxicity.
Pharmacodynamic Modeling. The development of cell culture media devoid of plasma drug binding proteins makes possible the application of colonyforming assays to the study of pharmacodynamic mechanisms. In particular, plasma protein-free media can be used to evaluate the binding of myelotoxic drugs to specific, purified plasma proteins, or plasma fractions. By analyzing the inhibition of colony formation as a result of drug exposure in the presence and absence of a particular plasma drugbinding protein, it is possible to estimate the KD of this interaction and the capacity of the particular protein. This is essentially an in situ Scatchard-type analysis, which has the distinct advantage that binding aihnities and number of binding sites can be estimated in real time without perturbing the system to separate free from bound drug. For example, the addition of suramin is directly toxic to mCFU-GM, inhibiting colony formation over a range of 10-100 gg/ml (Fig. 8 ). However, when physiologic concentrations of human serum albumin are incorporated into the media, this inhibitory range is increased to 1,000-10,000 uglml. Assuming that unbound drug Suramin (ug/mL) FiG. 8. -Inhibition ofmCFU-GM by suramin in the presence (+HSA) or absence (-HSA) of human serum albumin at its plasma concentration. Such data essentially represent an in situ Scatchard analysis from which the K, of drug binding to specific plasma proteins can be determined. This pharmacodynamic modeling will also be useful in predicting the effects of drug combination protocols upon drug displacement and the increased toxicity of a drug when plasma protein levels fall due to pathological conditions. is responsible for the biological effects, the difference in the myelotoxicity curves of suramin in the presence and absence of albumin can be used to calculate the percentage of drug bound over the range of concentrations. It is expected that this approach will provide much more accurate estimates of pharmacodynamic parameters of drug binding to plasma proteins. It could also be useful in identifying which of the plasma proteins are primarily responsible for drug binding and, therefore, which drugs may increase myelotoxicity when used in combination with the investigational agent. Furthermore, it may be useful in predicting changes in myelotoxicity during clinical trials in patients with pathologic conditions that alter the concentrations of drug-binding proteins in the plasma.
The Utility of In Vitro Myelotoxicity Assays for New Drug Development
Screening by Therapeutic Index. New drug leads for cancer and HIV are currently identified by screening approaches based only on efficacy. However, the usefulness of a drug in vivo depends on its ratio of efficacy to toxicity, in other words, its therapeutic index. The most useful drugs show therapeutic indices greater than 1, which indicate that they are more effective than they are toxic. Because myelosuppression is the dose-limiting toxicity TABLE IV.-Hypothetical examples illustrating the importance of screening by therapeutic index. Because myelotoxicity is usually dose-limiting in vivo, the IC,,, for CFU-GM can be used for the toxicity measurement for therapeutic index. Without toxicological evaluation, there is no rational basis for selecting compound A, B, or C, and compound E might be ignored for lack of potency even though it has a favorable therapeutic index. of most anti-cancer drugs and many anti-HIV agents, it would seem reasonable to incorporate myelotoxicity assays into the screening process to identify new drug leads. The importance of incorporating these data is illustrated in Table IV . In this table, compounds A, B, and C all show equal efficacy. With efficacy-based screening, there is no way of knowing which of these compounds to select for further development. However, by including in vitro myelotoxicity data, compound C is easily the most promising and compound B the least promising. In addition, screening by therapeutic index also prevents the exclusion of drugs that are weakly potent from further development. Compound E, for instance, in the efficacy screen would be identified as a relatively non-potent anti-cancer agent requiring 200 Am to inhibit cancer cell proliferation by 50%. However, this compound is less toxic to CFU-GM, and even at these high concentrations it still exhibits a favorable therapeutic index of 3.5. This compound is in fact suramin (9) , which in retrospect no drug development program would want to have missed.
A similar type of analysis can be applied to anti-HIV agents (Table V) . One can see that AZT and ddl show the highest therapeutic index, and this has been qualitatively validated by their clinical utility. Dideoxycytosine was found to be more myelotoxic and has been approved for only restricted use. Recalling Figs. 4 and 5, schedule dependency explains why AZT eventually produces neutropenia whereas ddl does not, although they show very similar therapeutic indices. This example teaches us that the most promising drug leads can be identified by combining in vitro toxicity data with efficacy data and interpreting them in light of the results of analyses of schedule dependency of toxicity and efficacy. With the currently available in vitro technology for evaluating efficacy and myelotoxicity, hematopoietic toxicology should be moved to its proper position in the anti-cancer and perhaps anti-HIV drug de-velopment process: as a contributor to new drug selection rather than a refinement/rejection tool immediately prior to phase I trials. Because therapeutic index is the basis of the effectiveness of a drug in an organism, toxicology assays should have equal status with efficacy assays.
Automated, High-Volume CFU Assays. An obstacle for incorporating toxicologic analyses into the drug discovery process is the lack of a high throughput, automated assay for collecting and analyzing colony inhibition data. We have begun to apply CapScan&copy; technology to the detection and quantitation of hematopoietic colonies grown in microcapillary tubes. Although a prototype machine lies in the future, CFU-GM colonies have been detectable in a microcapillary system that is amenable to automation. This automated system would also offer the advantage of small volume cultures, so that a complete myelotoxicity evaluation can be accomplished with 2-5 mg of drug.
DISCUSSION
In vitro technology has recently progressed to the point where quantitative evaluation of the myelotoxic potential of an investigational agent can be evaluated quickly and efflciently with a minimum of drug consumption. These in vitro systems offer distinct advantages over currently available preclinical models for evaluating myelotoxicity, not the least of which is the ability to analyze the toxicity of a compound on the ultimate target of interest, that is, hematopoietic cells from human marrow. In addition, highly accurate and quantitative assays can be used to derive important pharmacologic characteristics of an investigational agent, including its schedule dependency, mechanism of action, binding by plasma drug-binding proteins, and myelotoxicity relative to known anti-cancer or anti-HIV agents. Furthermore, these colony-forming assays are amenable to automation, which should allow them to eventually move into their rightful place in the drug discovery process by contributing to new drug screening based on human therapeutic indices calculated from in vitro data. Thus, the most effective drugs can immediately be identified and their development pursued, rather than waiting for toxicologic data to deny their entrance into clinical trials at a later date.
In closing, one other point should be made about the in vitro assays. Inhibition of colony formation is a quantitative indicator of a drug's potential to produce myelosuppression in the clinical setting. However, inhibition of colony formation could occur via several mechanisms. For example, either cytotoxicity or the induction of premature differentiation (before expansion of the progenitor pop-TABLE V.-Human therapeutic index-based screening applied to anti-HIV agents, assuming myelotoxicity is the dose-limiting toxicity. TC,o refers to the concentration that inhibits CFU-GM by 50% and EC,oo refers to the concentration that inhibits HIV replication by >_95% (4). ulation) could result in the apparent suppression of colony formation and likely cause cytopenia in vivo. Although other assays besides the colony-forming assays will have to be used to determine the mechanism of myelosuppression, these colony-forming assays still provide a tool for screening for the most effective way of compensating for drug-induced myelotoxicity. Taken together, the data presented show that the in vitro myelotoxicity assays are powerful tools in the hands of pharmacologists and toxicologists and will soon find their proper niche in new drug development and clinical trial planning.
